Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of SUL-238 in early untreated Parkinson's disease
NL-OMON59771Phase 2Recruiting
- Sponsor
- Gen Ilac Ve Saglik Urunleri
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing SUL-238 with Placebo (2 arms). Primary endpoint: Change in brain mitochondria-related metabolites by 31P-MRS. Started Mar 2026; status: recruiting.
02
Drugs
SUL-238
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON59771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59771.